Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus reduced‑dose R‑CHOP followed by lenalidomide maintenance in elderly diffuse large B cell lymphoma
KCT0003339Phase 2Not yet recruiting
- Sponsor
- Celgene Corporation
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Celgene Corporation. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0003339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003339.